Severe attack of Henoch-Schönlein purpura with neurologic involvement during adalimumab treatment for Crohn's disease.

Date publication

octobre 2019

Journal

Journal of Crohn's & colitis

Auteurs

Membres identifiés du Cancéropôle Est :
Pr CADIOT Guillaume

Tous les auteurs :
Condamina M, Diaz E, Jamart C, Loget J, Durlach A, Salmon JH, Cadiot G, Viguier M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31589303

Résumé

Tumour necrosis factor-α (TNF-α) inhibitors have revolutionized the management of chronic inflammatory conditions. A number of cutaneous adverse events have been reported with TNF inhibition, including vasculitis. Most reactions are mild and rarely warrant treatment withdrawal. Here we describe a patient with Crohn's disease treated with adalimumab in whom severe multivisceral Henoch-Schönlein purpura developed, including neurologic involvement, requiring definitive TNF blocker withdrawal.

Référence

J Crohns Colitis. 2019 Oct 7;: